Four More POM-To-P Switches In UK

30 January 1995

The UK Committee of Safety of Medicines has approved a further four medicines to be switched from Prescription-only to Pharmacy status. Consultation letter MLX 215 has been sent to interested parties for comment, and marks the outcome of the June/June switch "train" introduced last year, according to the Proprietary Association of Great Britain. The switch products are as follows:

- fluconazole, a triazole antifungal, currently available on prescription as Diflucan and manufactured by Pfizer. The over-the-counter indication will be vaginal candidiasis (thrush) in adults aged between 16 and 60. It is offered OTC on the following conditions; the maximum dose is 150mg; the route of administration is oral; and the pack size is limited to 150mg;

- pyrantel embonate, which is available on Rx from Pfizer under the brand name Combantrin. Its OTC indications will be the treatment of threadworm (enterobiasis) in adults and children aged over two. It is offered without prescription on the following conditions: the maximum daily dose is a single dose of 750mg in adults, 500mg in children aged 6-12, 250mg for 2-5 year olds; and pack size is limited to 750mg;

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight